Log ind

GN sets sight on global top three

Top picks in English:

GN Resound’s CEO Lars Viksmoen is clearly targeting a place in the top three of the so-called big six in the hearing devices industry – but he says the company could even make it to number two. See the full interview below.


larsViksmoen_highres.JPG
Foto: GN Resound/PR - Lars Viksmoen
by Henrik Tüchsen
Offentliggjort 23.10.13 kl. 14:15

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Danish diabetes patch enters US clinics

Reapplix.jpg Top picks in English:

After a new approval from FDA, Denmark's Reapplix is finally ready to send its biological patch for wound and ulcer treatment into US clinics. However, the commercial launch has to wait until next year and might require new funding, says Reapplix’s CEO.

Kåre Schultz joins the board of prominent fund

Top picks in English:

CEO in Lundbeck, Kåre Schultz, can add one more board membership to his CV. This time, he enters the board of a prominent Danish fund.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Onxeo cleared to continue liver cancer study

Top picks in English:

French-Danish biotech Onxeo has now received the recommendation to continue an important phase III study with its liver candidate drug Livatag. The first data from the study are expected soon.

GN sees progress for troubled US unit

Top picks in English:

The Danish hearing device giant GN Hearing has experienced Q1 growth rates unseen in years at the US subsidiary Beltone, says chief executive Anders Hedegaard. Beltone is crucial for GN’s growth in the US, estimates senior analyst.

Viagra copies cost less than 3 kroner

Top picks in English:

Since Viagra lost patent on June 24, 2013, generic versions of the drug have made the price drop by a staggering 97 %, according to a new analysis from a Danish pharmacy association. It could save Danish consumers millions per year.

Forsiden lige nu

Amerikansk medicokoncern fortsætter dansk vækst

REGNSKAB.jpg Medico & Rehab:

Edwards Lifesciences A/S kan endnu engang fremvise vækst på alle vigtige parametre, fremgår det af selskabets årsregnskab 2016.

Coloplast-chef scorer gevinst på 27 mio efter aktiesalg

Medico & Rehab:

Coloplasts topchef Lars Rasmussen kan efter salget af 100.000 aktier lægge en større formue i lommen.

Merck-middel får FDA-genvej mod mavekræft

Medicinal & Biotek:

Indikationsudvidelserne ser ud til at kunne fortsætte for Mercks kræftblockbuster Keytruda, som nu har fået en regulatorisk smutvej til det amerikanske marked inden for behandling af mavekræft.

Ny topchef ryster posen hos presset biotekselskab

Medicinal & Biotek:

Der er kommet en ny mand på topposten hos Alexion, som har været en hård periode igennem med anklager om snyd og bedrag, og med ham følger en stor ledelsesrokade, der dog ikke har imponeret markedet.

Janssen bruger gylden kupon på psoriasismiddel

Medicinal & Biotek:

Amerikanske Janssen har valgt at bruge en særlig kupon, som man fik fra FDA i 2012, til at fremskynde evalueringen af et nyt antistof til behandling af psoriasis. Sådanne kuponer er tidligere blevet solgt for flere milliarder kroner.

Pfizers version af Amgen-blockbuster får FDA-medvind

Medicinal & Biotek:

Instrukser til en ekspertkomite under FDA, som skal evaluere Pfizers biosimilære version af Amgens milliardsælgende anæmimiddel Epogen, tyder ifølge Endpoints på, at midlet inden længe vil blive godkendt i USA.

ANNONCE
ANNONCE


ANNONCE